0000929638-24-001452.txt : 20240412
0000929638-24-001452.hdr.sgml : 20240412
20240412161122
ACCESSION NUMBER: 0000929638-24-001452
CONFORMED SUBMISSION TYPE: 3/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240401
FILED AS OF DATE: 20240412
DATE AS OF CHANGE: 20240412
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ORBIMED ADVISORS LLC
CENTRAL INDEX KEY: 0001055951
ORGANIZATION NAME:
STATE OF INCORPORATION: DE
FILING VALUES:
FORM TYPE: 3/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36020
FILM NUMBER: 24841563
BUSINESS ADDRESS:
STREET 1: 601 LEXINGTON AVENUE
STREET 2: 54TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
BUSINESS PHONE: (212) 739-6400
MAIL ADDRESS:
STREET 1: 601 LEXINGTON AVENUE
STREET 2: 54TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: OrbiMed Capital GP VIII LLC
CENTRAL INDEX KEY: 0001845804
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 3/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36020
FILM NUMBER: 24841562
BUSINESS ADDRESS:
STREET 1: 601 LEXINGTON AVENUE
STREET 2: 54TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022-4629
BUSINESS PHONE: (212) 739-6400
MAIL ADDRESS:
STREET 1: 601 LEXINGTON AVENUE
STREET 2: 54TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022-4629
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Traws Pharma, Inc.
CENTRAL INDEX KEY: 0001130598
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12 PENNS TRAIL
CITY: NEWTOWN
STATE: PA
ZIP: 18940
BUSINESS PHONE: 267-759-3680
MAIL ADDRESS:
STREET 1: 12 PENNS TRAIL
CITY: NEWTOWN
STATE: PA
ZIP: 18940
FORMER COMPANY:
FORMER CONFORMED NAME: Onconova Therapeutics, Inc.
DATE OF NAME CHANGE: 20090526
FORMER COMPANY:
FORMER CONFORMED NAME: ONCONOVA THERAPEUTICS, INC.
DATE OF NAME CHANGE: 20090526
FORMER COMPANY:
FORMER CONFORMED NAME: ONCONOVA THERAPEUTICS INC
DATE OF NAME CHANGE: 20001226
3/A
1
form3.xml
X0206
3/A
2024-04-01
2024-04-03
0
0001130598
Traws Pharma, Inc.
TRAW
0001055951
ORBIMED ADVISORS LLC
601 LEXINGTON AVENUE, 54TH FLOOR
NEW YORK
NY
10022
true
See Remarks
0001845804
OrbiMed Capital GP VIII LLC
601 LEXINGTON AVENUE, 54TH FLOOR
NEW YORK
NY
10022
true
See Remarks
Common Stock
1045261
I
By OrbiMed Private Investments VIII, LP
Series C Preferred Stock
Common Stock
30916483
I
By OrbiMed Private Investments VIII, LP
Consists of (i) 885,532 shares of common stock of the Company, par value $0.01 per share ("Common Stock") received in exchange for shares of common stock of Trawsfynydd Therapeutics, Inc. ("Trawsfynydd") in connection with the acquisition (the "Merger") by Traws Pharma, Inc. (f/k/a Onconova Therapeutics, Inc., the "Company") of Trawsfynydd in accordance with the terms of an Agreement and Plan of Merger, dated April 1, 2024 (the "Merger Agreement"), by and among the Company, Traws Merger Sub I, Inc., Traws Merger Sub II, LLC and Trawsfynydd, pursuant to which, upon consummation of the Merger, all of the outstanding shares Trawsfynydd common stock were converted into shares of Common Stock on a 1:20.1291 basis pursuant to the terms of the Merger Agreement, and (ii) 159,729 shares of Common Stock received under a Securities Purchase Agreement dated April 1, 2024 (the "Securities Purchase Agreement"), by an among the Company, OrbiMed Private Investments VIII, LP ("OPI VIII") and TPAV, LLC.
The number of securities beneficially owned in the reporting persons' Form 3 filed on April 3, 2024 inadvertently did not include the 159,729 shares of Common Stock received pursuant to the Securities Purchase Agreement.
These shares are held of record by OPI VIII. OrbiMed Capital GP VIII LLC ("GP VIII"), is the general partner of OPI VIII. OrbiMed Advisors LLC ("OrbiMed Advisors"), is the managing member of GP VIII. By virtue of such relationships, OrbiMed Advisors and GP VIII may be deemed to have voting power and investment power over the securities held by OPI VIII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VIII.
Each of OrbiMed Advisors and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including any of the reporting persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Following stockholder approval of the conversion of the Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 10,000 shares of Common Stock, subject to certain limitations.
The amount or number of shares underlying the derivative security in the reporting persons' Form 3 filed on April 3, 2024 inadvertently did not include 5,072,820 shares underlying the Series C Preferred Stock received pursuant to the Securities Purchase Agreement.
Upon stockholder approval of the conversion of the Series C Preferred Stock into shares of common stock of the issuer as described herein, the reporting persons will be considered a "10% Owner" for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Until stockholder approval is obtained, the reporting persons disclaim beneficial ownership of the Series C Preferred Stock for purposes of Rule 16a-2 of the Exchange Act.
/s/ ORBIMED ADVISORS LLC, By: Douglas Coon, Chief Compliance Officer
2024-04-12
/s/ ORBIMED CAPITAL GP VIII LLC, By: Douglas Coon, Chief Compliance Officer
2024-04-12